利德曼：关于筹划重大资产重组的进展公告

Core Points - The company, Lideman, announced plans to acquire up to 70% of the shares held by certain shareholders of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. in a cash transaction [1] - Prior to this transaction, the company did not hold any shares in the target company; post-transaction, the target company will become a subsidiary controlled by Lideman [1] - The transaction is expected to constitute a major asset restructuring as defined by the regulations governing listed companies [1] Transaction Details - The company is currently advancing the specific matters related to the major asset restructuring, including conducting due diligence, auditing, and valuation of the target company [1] - Communication and negotiation with relevant parties regarding the major asset restructuring are ongoing, and no formal transaction documents have been signed yet [1] - The company will adhere to legal and regulatory requirements for decision-making and information disclosure as the transaction progresses [1]